The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Usually, PMR only affects adults over the age of 50. The average age of a person who has PMR is about 70 years old, with the highest prevalence in those older than 70. Women are three times as likely to get PMR as men. People of Western and Northern European descent are more likely to get this disease. It is more likely to affect people of Northern European origin; Scandinavians are especially vulnerable. About 50% of people with temporal arteritis also have polymyalgia rheumatica.
Stroke-like episodes before or after 40 years old Encephalopathy with seizures or dementia Blood lactic acidosis* or ragged red fibers on muscle biopsy Sensorineural hearing loss and mitochondrial diabetes are common features. Eyes may have a distinctive speckled pigment in the retina, referred to as a maculopathy. Family members may present differently.
The only feature that differentiates one brand from another is the product name in a standard color, position, font size, and style. In response to these regulations, Philip Morris International, Japan Tobacco Inc., British American Tobacco Plc., and Imperial Tobacco attempted to sue the Australian government. On August 15, 2012, the High Court of Australia dismissed the suit and made Australia the first country to introduce brand-free plain cigarette packaging with health warnings covering 90% of the back and 70% of the front packaging. This took effect on December 1, 2012. Similar policies have since been introduced in the United Kingdom, where standardised packaging of tobacco products regulations (SPOT) were introduced in 2015. These regulations were also challenged by cigarette manufacturers.
Sources: en.wikipedia.org
=== Mechanism of plasmids === Once the plasmid inserts itself into the transfected cell nucleus, it codes for a peptide string of a foreign antigen. On its surface the cell displays the foreign antigen with both histocompatibility complex (MHC) classes I and class II molecules. The antigen-presenting cell then travels to the lymph nodes and presents the antigen peptide and costimulatory molecule signalling to T-cell, initiating the immune response.
=== Cost === While the cost of the medication buprenorphine/naloxone is greater than buprenorphine alone, one analysis predicted the overall costs would be less in the United States due to a lower risk of misuse.
Using the present results, the fractional contribution of carbamino compounds of hemoglobin to the amount of carbon dioxide exchanged during the respiratory cycle was computed for a given set of physiological conditions in arterial and mixed venous blood. The computed value was found to be 10·5% in adult and 19% in fetal blood.
=== Dedicated magnet schools === Dedicated magnet schools are offered in the PGCPS system at the PreK-8th grade, elementary and middle school level only. As of 2012-13, Glenarden Woods and Heather Hills are the only full elementary-level dedicated magnet schools in the system. Dedicated magnet schools are "whole school" programs and differ from traditional comprehensive schools, as (1) all students at the school are enrolled and receive instruction in the magnet program and (2) traditional attendance areas for assigning students to a school are replaced by much larger geographical attendance zones, usually split between north county (areas north of Central Avenue) and south county (areas south of Central Avenue). Whole school, dedicated magnet programs are offered through the Creative and Performing Arts, French Immersion, Montessori, and Talented & Gifted Center magnet programs. Students receive specialized instruction that varies from the typical comprehensive program, offered at most other schools. Students are selected for the magnet programs through a magnet lottery for the French Immersion and Montessori programs and also for the Creative and Performing Arts program at the elementary school level. Acceptance into the Creative and Performing Arts program is through audition only at the middle school level. Acceptance into the TAG Centers at Glenarden Woods and Heather Hills Elementary Schools is through specialized TAG testing only.
Sources: en.wikipedia.org
==== Postmodification of homochiral MOFs ==== Lin and coworkers have shown that the postmodification of MOFs can be achieved to produce enantioselective homochiral MOFs for use as catalysts. The resulting 3D homochiral MOF {[Cd3(L)3Cl6] • 4DMF • 6MeOH • 3H2O} (L=(R)-6,6'-dichloro-2,2'-dihydroxyl-1,1'-binaphthyl-bipyridine) synthesized by Lin was shown to have a similar catalytic efficiency for the diethylzinc addition reaction as compared to the homogeneous analogue when was pretreated by Ti(OiPr)4 to generate the grafted Ti- BINOLate species. The catalytic activity of MOFs can vary depending on the framework structure. Lin and others found that MOFs synthesized from the same materials could have drastically different catalytic activities depending on the framework structure present.
may our temples be true harmonious ensembles of moral peace, civic education, and constant example for the work of good, which are so necessary in the current times that our Republic is going through... Not only the fulfillment of our Masonic duties, but the satisfaction as citizens of a Free homeland, to which we lend our selfless support, for the strengthening of republican institutions." On September 27, 1921, the Upper House of the Grand Lodge integrated the Association of Veteran Masons into its structure, where it had been an independent constituent of Cuban Freemasonry since 1893. In 1947, the Grand Lodge and the Supreme Council ratified the Treaty of Friendship and Mutual Recognition. On September 15, 1949, Grand Master Carlos M. Piñeiro y del Cueto issued Decree No. 284, creating the Cuban Academy of High Masonic Studies. In 1936, there were 195 Lodges in Cuba. From 1945 to 1959, the membership of Freemasonry in Cuba had doubled. By 1959, there were over 34,000 Freemasons in Cuba. By the time of the collapse of the Republic of Cuba, the Grand Lodge of Cuba maintained 400 regular Lodges.
Many biologics, skin substitutes, biomembranes and scaffolds have been developed to facilitate wound healing through various mechanisms. Other recent developments has been the renewed focus on the prominent patient concern of pain. Burn patients and others affected by severe wounds often report pain as the dominant negative impact of the wounds on their lives. Clinical management of the pain associated with chronic wounds has been an emergency wound treatment priority and is now viewed as an integral part of treatment.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.